Liu Lei, Hao Xiaomeng, Song Zian, Zhi Xiangcheng, Zhang Sheng, Zhang Jin
The Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Huanhu West Road, Tianjin, 300000, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Sci Rep. 2021 Mar 18;11(1):6360. doi: 10.1038/s41598-021-85899-8.
Family history is a major risk factor for breast cancer; approximately 5-10% cases of breast cancer are associated with a family history. Herein, we investigated the link between family history and breast cancer features to elucidate the importance of family history in the diagnosis and treatment of breast cancer. Data from 10,549 patients with breast cancer were collected from 2014 to 2017. Detailed information about the family history of the patients including the degree and number of relatives affected and the types of cancer was recorded. The tumors were pathologically and clinically classified based on the stage, grade, ER, PR, HER2, Ki-67 status, and subtypes, according to standard guidelines. Data were analyzed using χ test and multiple logistic regression. Patients with a family history of other cancer types were significantly older at diagnosis than patients with a family history of breast/ovarian cancer (p = 0.002) and those without a family history of cancer (p < 0.001). Patients without a family history of cancer were typically diagnosed at a later stage, including high frequency in N2 (p = 0.035) and TNM stage III (p = 0.015). Compared with patients with second-/third-degree relatives, those with first-degree relatives having breast/ovarian cancer had a higher median age (54.1, p < 0.001) at diagnosis and showed more advanced disease. No significant difference was found between ER, PR, and HER2 status in patients with and without a family history of cancer. Family history of breast cancer can influence the cancer characteristics of the patients at diagnosis, especially patient age, tumor stage, and grade.
家族史是乳腺癌的一个主要风险因素;约5%-10%的乳腺癌病例与家族史有关。在此,我们研究了家族史与乳腺癌特征之间的联系,以阐明家族史在乳腺癌诊断和治疗中的重要性。收集了2014年至2017年10549例乳腺癌患者的数据。记录了患者家族史的详细信息,包括受影响亲属的程度和数量以及癌症类型。根据标准指南,对肿瘤进行病理和临床分期、分级、雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)、Ki-67状态及亚型分类。采用χ检验和多元逻辑回归分析数据。有其他癌症类型家族史的患者在诊断时的年龄显著大于有乳腺癌/卵巢癌家族史的患者(p = 0.002)和无癌症家族史的患者(p < 0.001)。无癌症家族史的患者通常在较晚阶段被诊断,包括N2期(p = 0.035)和TNM III期(p = 0.015)的高频率。与有二级/三级亲属的患者相比,有一级亲属患乳腺癌/卵巢癌的患者在诊断时的中位年龄更高(54.1岁,p < 0.001),且疾病进展更明显。有癌症家族史和无癌症家族史的患者在ER、PR和HER2状态方面未发现显著差异。乳腺癌家族史可影响患者诊断时的癌症特征,尤其是患者年龄、肿瘤分期和分级。